Lisata Therapeutics has entered into a binding term sheet to be acquired by Kuva Labs. Under the agreement, Kuva Labs will commence a tender offer to purchase all outstanding shares of Lisata for $4.00 per share in cash. In addition, Lisata stockholders will be eligible to receive two non-tradeable contingent value rights, each valued at $1.00 per share, tied to specific future milestones related to certepetide rights in Greater China and regulatory filings for commercialization. The transaction has been unanimously approved by the boards of both companies, with a definitive purchase agreement expected before February 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629346-en) on January 21, 2026, and is solely responsible for the information contained therein.